CLRB Cellectar Biosciences, Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 13, 2026
$1,78
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$1,7852 haftanın en düşüğü
$6,5252 haftanın en yükseği
Piyasa Değeri (MRQ)
$15M
P/E
-0.4
Hisse Başına Kâr
$-8.35
rozetleriniz
52 Haftlık Aralık
$2–$7
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$12
P/E
-0.4
ROE
·
Net Kâr Marjı
·
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
CLRB Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$1.78
Piyasa Değeri (MRQ)
$15M
P/E
-0.4
Hisse Başına Kâr
$-8.35
52 Haftlık Aralık
$2–$7
CLRB Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Hisse bölünmeleri
| Ex-tarihi | Bölünme | Tür |
|---|---|---|
| 24 Haziran 2025 | 1-for-30 | Ters |
| 22 Temmuz 2022 | 1-for-10 | Ters |
| 17 Temmuz 2018 | 1-for-10 | Ters |
| 07 Mart 2016 | 1-for-10 | Ters |
| 16 Haziran 2014 | 1-for-20 | Ters |
| 11 Nisan 2011 | 1-for-153 | Ters |
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Hisse Başına Kâr$-8.352022-12-31 → 2025-12-31
Serbest Nakit Akışı·2023-12-31 → 2024-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | CLRB | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E | -0.45Y ort. ≈-8.1 | ≈-8.1 | · | · | |
| F/D (MRQ) | 0.5 | · | 2.0 | Düşük değerli | |
| Price / Tangible Book (Fiyat / Maddi Defter Değeri) | 1.5 | · | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
Bu oran grubu için henüz veri yok
Bu oran grubunu hesaplamak için henüz yeterli temel veriye sahip değil.
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | CLRB | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Cari Oran (MRQ) | 6.7 | · | 1.4 | Güçlü likidite |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Bu oran grubu için henüz veri yok
Bu oran grubunu hesaplamak için henüz yeterli temel veriye sahip değil.
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
Bu oran grubu için henüz veri yok
Bu oran grubunu hesaplamak için henüz yeterli temel veriye sahip değil.
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
22.9%
Sonraki Rapor
Kas 11, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 13, 2026 | $-0.57 | $-0.49 | -15.6% |
| 31 Mart 2026 | May 14, 2026 | $-1.30 | $-1.92 | 32.4% |
| 31 Aralık 2025 | $-1.29 | $-2.34 | 44.9% | |
| 30 Eylül 2025 | $-1.41 | $-2.58 | 45.3% | |
| 30 Haziran 2025 | $-3.39 | $-3.98 | 14.8% | |
| 31 Mart 2025 | $-4.20 | $-5.00 | 16.0% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $11M | $26M | $27M | $18M | $18M | $10M | $9M | $7M | $9M | $5M | $5M | $6M | |
| SG&A Expense | $11M | $26M | $12M | $11M | $7M | $5M | $5M | $5M | $4M | $5M | $3M | $4M | |
| Operating Expenses | $23M | $52M | $39M | $29M | $24M | $15M | $14M | $13M | $14M | $9M | $9M | $10M | |
| Operating Income | $-23M | $-52M | $-39M | $-29M | $-24M | $-15M | $-14M | $-13M | $-14M | $-9M | $-9M | $-10M | |
| Other Non-op | $1M | $7M | $-4M | $-3M | $8.9K | $196.2K | $85.7K | $91.7K | $38.7K | $3M | $3M | $2M | |
| Pretax Income | $-22M | $-45M | $-43M | $-32M | $-24M | · | · | · | · | · | · | · | |
| Income Tax | · | $66.0K | $-60.0K | $-60.0K | · | · | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-22M | $-45M | $-43M | $-32M | $-24M | $-15M | $-14M | $-13M | $-14M | $-6M | $-5M | $-8M | |
| EPS (Basic) | $-8.35 | $-36.52 | $-3.50 | $-4.51 | $-4.35 | $-0.76 | · | · | · | · | · | · | |
| EPS (Diluted) | $-8.35 | $-41.89 | $-3.50 | $-4.51 | $-4.35 | $-1.84 | · | · | · | · | · | · | |
| Shares (Basic) | 2,608,317 | 1,220,749 | 12,221,571 | 7,055,665 | 5,551,572 | 19,812,659 | · | · | · | · | · | · | |
| Shares (Diluted) | 2,608,317 | 1,238,125 | 12,221,571 | 7,055,665 | 5,551,572 | 19,812,659 | · | · | · | · | · | · | |
| EBITDA | · | $-51M | $-39M | · | $-24M | · | $-14M | $-13M | $-12M | $-9M | $-8M | $-10M |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $13M | $23M | $10M | $20M | $36M | $57M | $11M | $13M | $10M | $11M | $4M | $9M | |
| Prepaid Expense | $842.4K | $961.7K | $888.2K | $663.2K | $867.5K | $774.4K | $771.0K | $641.2K | $412.2K | $693.6K | $267.8K | $220.6K | |
| Current Assets | $14M | $24M | $10M | $21M | $37M | $58M | $11M | $14M | $10M | $12M | $4M | $10M | |
| PP&E (Net) | $549.4K | $757.1K | $1M | $418.6K | $344.5K | $356.0K | $435.1K | $543.3K | $244.7K | $1M | $2M | $2M | |
| PP&E (Gross) | · | · | $2M | $1M | $889.3K | $759.7K | $744.5K | $724.5K | $6M | $6M | $6M | $6M | |
| Accum. Depreciation | $1M | $1M | $885.0K | $692.5K | $544.8K | $403.7K | $309.4K | $181.2K | $6M | $4M | $4M | $4M | |
| Goodwill | · | · | · | · | · | · | $0 | $0 | $2M | $2M | $2M | $2M | |
| Other Non-current Assets | $29.8K | $29.8K | $29.8K | $81.2K | $6.2K | $6.2K | $6.2K | $18.1K | $11.9K | $11.9K | $11.9K | $11.9K | |
| Total Assets | $15M | $25M | $12M | $22M | $37M | $59M | $12M | $15M | $13M | $15M | $8M | $13M | |
| Accounts Payable | $4M | $4M | $6M | $3M | $1M | $1M | $1M | $612.0K | $933.0K | $1M | $675.9K | $934.0K | |
| Short-term Debt | · | · | · | · | · | · | · | · | $0 | $86.6K | $243.6K | $119.9K | |
| Current Liabilities | $5M | $9M | $25M | $12M | $4M | $4M | $3M | $2M | $2M | $2M | $6M | $6M | |
| Capital Leases | $309.4K | $409.6K | $494.0K | $553.0K | $166.3K | $301.7K | $421.6K | $0 | $2.2K | $5.2K | $8.0K | $11.1K | |
| Total Liabilities | $5M | $10M | $26M | $12M | $4M | $4M | $3M | $2M | $2M | $2M | $6M | $7M | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | $330.2K | $450.0K | |
| Total Debt | · | · | · | · | · | · | · | · | $0 | $86.6K | $243.6K | · | |
| Common Stock | $42 | $15 | $207 | $94 | $61 | $454 | $94 | $47 | $16 | $104 | $9 | $8 | |
| Paid-in Capital | $277M | $261M | $183M | $168M | $183M | $162M | $120M | $108M | $94M | $83M | $66M | $66M | |
| Retained Earnings | $-269M | $-247M | $-203M | $-160M | $-151M | $-127M | $-112M | $-98M | $-84M | $-71M | $-65M | $-59M | |
| Stockholders' Equity | $9M | $14M | $-15M | $8M | $29M | $55M | $9M | $13M | $11M | $14M | $2M | $7M | |
| Liabilities + Equity | $15M | $25M | $12M | $22M | $37M | $59M | $12M | $15M | $13M | $15M | $8M | $13M | |
| Shares Outstanding | 4,240,129 | 1,535,996 | 20,744,110 | 9,385,272 | 6,110,125 | 45,442,729 | 9,386,689 | 4,732,387 | 1,666,144 | 10,368,325 | 858,140 | 756,276 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $213.6K | $291.7K | $192.4K | $148.4K | $149.9K | $141.5K | $132.8K | $82.3K | $2M | $356.7K | $362.5K | $367.2K | |
| Stock-based Comp | $2M | $4M | $2M | $1M | $1M | $467.5K | $866.8K | $721.2K | $758.8K | $529.2K | $447.3K | $850.4K | |
| Deferred Tax | $-7M | $-20M | $-15M | $-10M | $-8M | $-5M | $-8M | $-3M | $16M | $-4M | $-3M | $-3M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | $204.0K | · | |
| Other Non-cash | · | $12M | $23M | · | · | · | $10M | $4M | $-15M | $965.5K | $-464.7K | $1M | |
| Operating Cash Flow | $-23M | $-48M | $-32M | $-25M | $-23M | $-14M | $-12M | $-11M | $-11M | $-8M | $-8M | $-9M | |
| CapEx | $5.9K | $104.2K | $864.0K | $226.0K | $141.4K | $62.4K | $24.5K | $385.0K | $346.7K | $72.3K | $58.5K | $29.6K | |
| Investing Cash Flow | $-5.9K | $-104.2K | $-864.0K | $-226.0K | $-141.4K | $-62.4K | $-24.5K | $-330.0K | $-346.7K | $-72.3K | · | · | |
| Debt Issued | · | · | · | · | · | $184.0K | · | · | · | · | · | · | |
| Net Debt Issued | · | · | · | · | · | · | · | $0 | $-86.6K | $-243.6K | $-119.8K | · | |
| Stock Issued | · | · | · | $10M | $34.9K | $60M | $9M | $9M | $5M | $12M | $3M | $12M | |
| Net Stock Activity | · | · | · | · | $34.9K | · | $9M | $9M | $5M | $12M | $3M | $12M | |
| Financing Cash Flow | $13M | $61M | $23M | $10M | $1M | $61M | $9M | $15M | $10M | $16M | · | · | |
| Net Change in Cash | $-10M | $14M | $-10M | $-16M | $-21M | $47M | $-3M | $3M | $-1M | $8M | $-6M | $7M | |
| Free Cash Flow | · | $-48M | $-33M | · | $-23M | · | $-12M | $-12M | $-11M | $-8M | $-8M | $-9M |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | · | -237.4% | · | · | -50.3% | · | -103.2% | -94.8% | -96.2% | -53.9% | -52.3% | · | |
| ROE | · | -302.7% | · | · | -67.3% | · | -132.4% | -87.8% | -147.8% | -81.4% | -131.7% | · | |
| ROIC | · | -362.8% | · | · | · | · | · | · | · | · | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 2.6 | · | · | 9.2 | · | 4.1 | 8.6 | 5.2 | 7.5 | 0.7 | · | |
| Quick Ratio | · | 2.5 | · | · | 8.9 | · | 3.8 | 8.2 | 4.7 | 7.0 | 0.7 | · | |
| Debt / Equity | · | · | · | · | · | · | · | · | 0.0 | 0.0 | 0.1 | · |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | · | $0.31 | · | · | $0.54 | · | $0.97 | $2.80 | $0.65 | $15.78 | $1.92 | · | |
| Cash Flow / Share | · | $-1.28 | $-2.65 | · | $-0.41 | · | · | · | · | · | · | · | |
| Cash / Share | · | $0.51 | · | · | $0.58 | · | $1.13 | $2.80 | $0.60 | $13.34 | $4.50 | · | |
| EPS (TTM) | $-8.35 | $-41.89 | $-3.50 | $-4.51 | $-4.35 | $-1.84 | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-22M | $-45M | $-43M | $-32M | $-24M | $-15M | $-14M | $-13M | $-14M | $-6M | $-5M | $-8M | |
| Market Cap | · | $415M | · | · | $12.10B | · | $6.34B | $2.20B | $68.48B | $3.14B | $19.05B | · | |
| Enterprise Value | · | · | · | · | · | · | · | · | $68.47B | $3.13B | $19.05B | · | |
| P/E | -0.4 | -0.2 | -23.7 | -11.4 | -45.5 | -339.1 | · | · | · | · | · | · | |
| P/B | · | 29.0 | · | · | 366.1 | · | 699.4 | 165.9 | 6367.5 | 232.0 | 11547.3 | · | |
| P / Tangible Book | 1.5 | 29.0 | · | 59.1 | 416.3 | 517.5 | · | · | · | · | · | · | |
| P / Cash Flow | · | -8.7 | · | · | -536.1 | · | -541.8 | -192.3 | -6213.9 | -379.2 | -2319.6 | · | |
| P / FCF | · | -8.7 | · | · | -532.7 | · | -540.7 | -186.1 | -6024.3 | -375.9 | -2303.2 | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | -5679.7 | -344.2 | -2268.8 | · | |
| EV / FCF | · | · | · | · | · | · | · | · | -6023.4 | -374.6 | -2302.8 | · | |
| Earnings Yield | -283.0% | -465.4% | -4.2% | -8.8% | -2.2% | -0.29% | · | · | · | · | · | · |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $5M | $3M | $3M | $3M | $2M | $3M | $6M | $5M | $7M | $7M | $8M | $7M | $6M | $6M | $4M | $5M | |
| SG&A Expense | $3M | $3M | $3M | $2M | $4M | $3M | $7M | $8M | $6M | $5M | $5M | $2M | $2M | $2M | $3M | $3M | |
| Operating Expenses | $7M | $6M | $6M | $5M | $6M | $6M | $13M | $13M | $14M | $12M | $13M | $9M | $8M | $9M | $7M | $8M | |
| Operating Income | $-7M | $-6M | $-6M | $-5M | $-6M | $-6M | $-13M | $-13M | $-14M | $-12M | $-13M | $-9M | $-8M | $-9M | $-7M | $-8M | |
| Other Non-op | $265.4K | $140.0K | $395.4K | $406.8K | $589.6K | $-203.0K | $10M | $-1M | $13M | $-15M | $5M | $-8M | $-2M | $2M | $-3M | $304.2K | |
| Net Income | $-7M | $-6M | $-5M | $-4M | $-5M | $-7M | $-2M | $-15M | $-919.4K | $-27M | $-8M | $-18M | $-10M | $-7M | $-10M | $-8M | |
| EPS (Basic) | $-0.57 | $-1.33 | $-3.41 | $-1.41 | $-3.39 | $-4.30 | $-23.66 | $-11.18 | $-0.77 | $-0.91 | $-0.41 | $-1.55 | $-0.90 | $-0.64 | $-1.01 | $-1.23 | |
| EPS (Diluted) | $-0.57 | $-1.33 | $-3.41 | $-1.41 | $-3.39 | $-4.30 | $-23.42 | $-12.13 | $-5.43 | $-0.91 | $-0.41 | $-1.55 | $-0.90 | $-0.64 | $-1.01 | $-1.23 | |
| Shares (Basic) | 12,231,851 | 4,240,129 | · | 3,162,040 | 1,608,799 | 1,535,995 | · | 1,311,197 | 1,193,981 | 29,346,679 | · | 11,308,738 | 11,261,217 | 11,261,217 | · | 6,110,119 | |
| Shares (Diluted) | 12,231,851 | 4,240,129 | · | 3,162,040 | 1,608,799 | 1,535,995 | · | 1,326,474 | 1,248,210 | 29,346,679 | · | 11,308,738 | 11,261,217 | 11,261,217 | · | 6,110,119 | |
| EBITDA | $-7M | $-6M | · | $-5M | $-6M | $-6M | · | $-13M | $-14M | $-12M | · | $-9M | $-8M | $-9M | · | $-8M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $34M | $8M | $13M | $13M | $11M | $14M | $23M | $34M | $26M | $40M | $10M | $19M | $5M | $13M | $20M | $18M | |
| Prepaid Expense | $883.7K | $920.0K | $842.4K | $1M | $2M | $987.5K | $961.7K | $2M | $2M | $1M | $888.2K | $1M | $456.7K | $1M | $663.2K | $975.9K | |
| Current Assets | $35M | $9M | $14M | $14M | $13M | $15M | $24M | $36M | $28M | $41M | $10M | $20M | $6M | $14M | $21M | $19M | |
| PP&E (Net) | $304.2K | $339.7K | $549.4K | $595.3K | $647.5K | $700.8K | $757.1K | $910.1K | $978.7K | $1M | $1M | $893.5K | $337.4K | $376.1K | $418.6K | $338.9K | |
| PP&E (Gross) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $1M | · | |
| Accum. Depreciation | · | · | $1M | · | · | · | $1M | · | · | · | $885.0K | · | · | · | $692.5K | · | |
| Other Non-current Assets | $23.6K | $29.8K | $29.8K | $29.8K | $29.8K | $29.8K | $29.8K | $29.8K | $29.8K | $29.8K | $29.8K | $6.2K | $6.2K | $6.2K | $81.2K | · | |
| Total Assets | $37M | $11M | $15M | $15M | $14M | $16M | $25M | $37M | $29M | $43M | $12M | $22M | $7M | $15M | $22M | $19M | |
| Accounts Payable | $5M | $5M | $1M | $4M | $5M | $4M | $4M | $8M | $6M | $7M | $6M | $8M | $6M | $7M | $3M | $6M | |
| Current Liabilities | $5M | $5M | $5M | $5M | $6M | $6M | $9M | $20M | $15M | $29M | $25M | $16M | $6M | $7M | $12M | $7M | |
| Capital Leases | $2M | $2M | $309.4K | $335.9K | $361.5K | $386.2K | $409.6K | $431.9K | $453.5K | $474.3K | $494.0K | $512.8K | $530.9K | $548.3K | $553.0K | $53.8K | |
| Total Liabilities | $7M | $6M | $5M | $5M | $6M | $6M | $10M | $21M | $16M | $29M | $26M | $17M | $7M | $8M | $12M | $7M | |
| Common Stock | $83 | $42 | $42 | $32 | $18 | $461 | $15 | $406 | $358 | $332 | $207 | $99 | $97 | $97 | $94 | $61 | |
| Paid-in Capital | $312M | $278M | $277M | $271M | $265M | $262M | $261M | $247M | $235M | $225M | $183M | $195M | $194M | $194M | $168M | $184M | |
| Retained Earnings | $-282M | $-275M | $-269M | $-264M | $-259M | $-254M | $-247M | $-245M | $-230M | $-229M | $-203M | $-210M | $-196M | · | $-160M | $-172M | |
| Stockholders' Equity | $30M | $3M | $9M | $8M | $6M | $8M | $14M | $15M | $12M | $13M | $-15M | $-13M | $-467.0K | $7M | $8M | $13M | |
| Liabilities + Equity | $37M | $11M | $15M | $15M | $14M | $16M | $25M | $37M | $29M | $43M | $12M | $22M | $7M | $15M | $22M | $19M | |
| Shares Outstanding | 8,252,108 | 4,240,129 | 4,240,129 | 3,192,040 | 1,812,040 | 46,079,875 | 1,535,996 | 40,566,534 | 35,848,924 | 33,164,466 | 20,744,110 | 9,918,384 | 9,740,507 | 9,740,507 | 9,385,272 | 6,110,119 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | $49.5K | $52.3K | $55.6K | $56.3K | $68.6K | $68.6K | $66.0K | $88.5K | $70.0K | $41.2K | $38.6K | $42.6K | $38.2K | $33.0K | |
| Stock-based Comp | $428.3K | $451.9K | $567.8K | $567.8K | $565.4K | $562.7K | $1M | $2M | $799.2K | $454.4K | $1M | $497.9K | $419.8K | $408.2K | $361.4K | $367.8K | |
| Other Non-cash | · | · | · | · | · | $-3M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-6M | $-5M | $-4M | $-4M | $-5M | $-9M | $-11M | $-9M | $-14M | $-13M | $-10M | $-8M | $-8M | $-7M | $-7M | $-7M | |
| CapEx | $0 | $3.4K | · | · | · | · | $61.3K | $0 | $21.3K | $21.6K | $266.8K | · | · | · | $117.9K | $7.1K | |
| Investing Cash Flow | $0 | $-3.4K | · | · | · | · | $-61.3K | $0 | $-21.3K | $-21.6K | $-266.8K | · | · | · | $-117.9K | $-7.1K | |
| Financing Cash Flow | · | · | $5M | $6M | · | · | $0 | $18M | $1 | $44M | $441.0K | $22M | $0 | $3 | · | · | |
| Net Change in Cash | $26M | $-5M | $641.7K | $2M | $-3M | $-9M | $-11M | $8M | $-14M | $30M | $-9M | $14M | $-8M | $-7M | $2M | $-7M | |
| Free Cash Flow | · | $-5M | · | · | · | · | · | · | · | $-13M | · | · | · | · | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -27.5% | -41.6% | · | -17.1% | -25.3% | -22.4% | · | -49.8% | -5.1% | · | · | -67.2% | -50.7% | · | · | -25.5% | |
| ROE | -38.6% | -97.6% | · | -38.4% | -59.0% | -63.6% | · | -1618.5% | -15.4% | · | · | 4559.8% | -83.4% | · | · | -30.4% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.7 | 1.9 | · | 2.8 | 2.2 | 2.5 | · | 1.8 | 1.8 | 1.4 | · | 1.2 | 0.9 | 2.0 | · | 2.9 | |
| Quick Ratio | 6.5 | 1.7 | · | 2.6 | 1.9 | 2.3 | · | 1.7 | 1.7 | 1.4 | · | 1.2 | 0.8 | 1.8 | · | 2.7 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.62 | $0.79 | · | $2.51 | $3.36 | $0.18 | · | $0.37 | $0.35 | $0.38 | · | $-1.35 | $-0.05 | $0.75 | · | $2.09 | |
| Cash Flow / Share | · | $-1.14 | · | · | · | $-0.20 | · | · | · | $-0.46 | · | · | · | $-0.64 | · | · | |
| Cash / Share | $4.12 | $1.97 | · | $3.93 | $6.09 | $0.30 | · | $0.84 | $0.72 | $1.21 | · | $1.91 | $0.53 | $1.30 | · | $2.91 | |
| EPS (TTM) | $-6.72 | $-9.54 | · | $-32.52 | $-43.24 | $-45.28 | · | $-18.88 | $-8.30 | $-3.77 | · | $-4.10 | $-3.78 | $-3.80 | · | $-5.28 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-22M | $-21M | · | $-19M | $-29M | $-25M | · | $-50M | $-53M | $-62M | · | $-45M | $-35M | $-31M | · | $-25M | |
| Market Cap | $23M | $11M | · | $18M | $13M | $442M | · | $2.60B | $2.69B | $3.96B | · | $786M | $570M | $418M | · | $616M | |
| P/E | -0.4 | -0.3 | · | -0.2 | -0.2 | -0.2 | · | -3.4 | -9.0 | -31.7 | · | -19.3 | -15.5 | -11.3 | · | -19.1 | |
| P/B | 0.8 | 3.2 | · | 2.2 | 2.1 | 53.6 | · | 171.7 | 217.2 | 316.8 | · | -58.8 | -1220.2 | 57.0 | · | 48.3 | |
| P / Tangible Book | 0.8 | 3.2 | · | 2.2 | 2.1 | 53.6 | · | 171.7 | 217.2 | 316.8 | · | · | · | 57.0 | · | 48.3 | |
| P / Cash Flow | · | -2.2 | · | · | · | -47.1 | · | · | · | -296.4 | · | · | · | -58.2 | · | · | |
| Earnings Yield | -241.7% | -375.6% | · | -580.7% | -608.2% | -471.7% | · | -29.4% | -11.1% | -3.2% | · | -5.2% | -6.5% | -8.9% | · | -5.2% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
|---|---|---|---|---|---|
| Net Gelir | $-22M | $-45M | $-43M | · | · |
| Seyreltilmiş Hisse Başı Kâr | $-8.35 | $-41.89 | $-3.50 | · | · |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
|---|---|---|---|---|---|
| Cari Oran | · | 2.6 | · | · | · |
| Cari Oran | · | 2.5 | · | · | · |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | · | $-48M | $-33M | · | · |
Kurumsal Sahipler (13F) 29 dosya · $8.5M toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
29
Tutulan Değer
$8.5M
Yeni pozisyonlar
13
Çıkan pozisyonlar
4
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 13 (+9 önceki Ç'ye göre) | 4 (+1 önceki Ç'ye göre) | 6 (+4 önceki Ç'ye göre) | 2 (-1 önceki Ç'ye göre) | +2.7M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| Caligan Partners LP | $1.306.594 | 469.998 | 15,30% | Hisse senetleri |
| STEMPOINT CAPITAL LP | $986.728 | 354.938 | 11,56% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $910.080 | 327.367 | 10,66% | Hisse senetleri |
| SILVERARC CAPITAL MANAGEMENT, LLC | $894.404 | 321.728 | 10,48% | Hisse senetleri |
| Bleichroeder LP | $802.528 | 288.679 | 9,40% | Hisse senetleri |
| Balyasny Asset Management L.P. | $611.600 | 220.000 | 7,16% | Hisse senetleri |
| Nantahala Capital Management, LLC | $611.594 | 219.998 | 7,16% | Hisse senetleri |
| Empery Asset Management, LP | $527.102 | 189.605 | 6,17% | Hisse senetleri |
| DIADEMA PARTNERS LP | $384.588 | 138.341 | 4,50% | Hisse senetleri |
| Stonepine Capital Management, LLC | $290.649 | 104.550 | 3,40% | Hisse senetleri |
| VANGUARD GROUP INC | $262.904 | 89.120 | 3,08% | Hisse senetleri |
| Persistent Asset Partners Ltd | $258.493 | 92.983 | 3,03% | Hisse senetleri |
| BOOTHBAY FUND MANAGEMENT, LLC | $236.492 | 85.069 | 2,77% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $148.323 | 53.351 | 1,74% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $128.492 | 46.220 | 1,51% | Hisse senetleri |
| Sequoia Financial Advisors, LLC | $60.743 | 21.850 | 0,71% | Hisse senetleri |
| Riverview Capital Advisers, LLC | $50.051 | 10.384 | 0,59% | Hisse senetleri |
| NORTHERN TRUST CORP | $41.252 | 14.839 | 0,48% | Hisse senetleri |
| BlackRock, Inc. | $13.163 | 4.735 | 0,15% | Hisse senetleri |
| UBS Group AG | $8.599 | 3.093 | 0,10% | Hisse senetleri |
| BARCLAYS PLC | $1.560 | 561 | 0,02% | Hisse senetleri |
| MORGAN STANLEY | $1.418 | 510 | 0,02% | Hisse senetleri |
| TD Waterhouse Canada Inc. | $178 | 63 | 0,00% | Hisse senetleri |
| ACADIAN ASSET MANAGEMENT LLC | $46 | 16.577 | 0,00% | Hisse senetleri |
| SBI Securities Co., Ltd. | $31 | 11 | 0,00% | Hisse senetleri |
| OSAIC HOLDINGS, INC. | $18 | 7 | 0,00% | Hisse senetleri |
| US BANCORP \DE\ | $8 | 3 | 0,00% | Hisse senetleri |
| JONES FINANCIAL COMPANIES LLLP | $8 | 3 | 0,00% | Hisse senetleri |
| DANSKE BANK A/S | $6 | 2 | 0,00% | Hisse senetleri |
Aktivistler ve %5+ sahipler 3 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Wisconsin Alumni Research Foundation 2) ×2 başvurular | 02 Aralık 2016 | · | İlk başvuru | Pasif yatırım | SEC |
| Austin W. Marxe, David M. Greenhouse, Adam Stettner (2) | 29 Ocak 2015 | · | İlk başvuru | Pasif yatırım | SEC |
| Austin W. Marxe, David M. Greenhouse and Adam C. Stettner | 09 Eylül 2014 | · | İlk başvuru | Pasif yatırım | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 24 içeriden öğrenenler · 12 yöneticiler · 9 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| James V Caruso | President & CEO | 07 Temmuz 2026 A | 20.318 | 2 | 0 | $25.258 |
| Simon Pedder | President and CEO | 20 Ağustos 2014 P | 13.300 | 0 | 0 | $0 |
| Chad J Kolean | CFO | 07 Temmuz 2026 A | 6.418 | 0 | 0 | $0 |
| Brian M Posner | Chief Financial Officer | 17 Ocak 2019 A | · | 0 | 0 | $0 |
| Jarrod Longcor | Chief Operating Officer | 07 Temmuz 2026 A | 20.451 | 2 | 0 | $25.258 |
| Andrei Shustov | Senior Vice President, Medical | 14 Haziran 2024 A | 55.038 | 0 | 0 | $0 |
| Darrell Shane Lea | Chief Commercial Officer | 14 Haziran 2024 A | 39.599 | 0 | 0 | $0 |
| John E. Friend II | Chief Medical Officer | 04 Mart 2021 A | 100.000 | 0 | 0 | $0 |
| Igor D Grachev | Chief Medical Officer | 06 Ocak 2020 A | · | 0 | 0 | $0 |
| Jamey P Weichert | Chief Scientific Officer | 12 Mayıs 2016 A | · | 0 | 0 | $0 |
| John Patrick Genn | VP of Business Development | 26 Şubat 2015 A | · | 0 | 0 | $0 |
| Cameron Szakacs | VP of Clinical Development | 24 Kasım 2014 A | · | 0 | 0 | $0 |
| Andrew Gu | Yönetim kurulu üyesi | 07 Temmuz 2026 A | · | 0 | 0 | $0 |
| Asher Chanan-Khan | Yönetim kurulu üyesi | 07 Temmuz 2026 A | · | 0 | 0 | $0 |
| Douglas J Swirsky | Yönetim kurulu üyesi | 07 Temmuz 2026 A | 25.000 | 0 | 0 | $0 |
| John Neis | Yönetim kurulu üyesi | 07 Temmuz 2026 A | 10 | 0 | 1 | $-733 |
| Frederick W Driscoll | Yönetim kurulu üyesi | 07 Temmuz 2026 A | 19.417 | 0 | 0 | $0 |
| Stephen A Hill | Yönetim kurulu üyesi | 24 Haziran 2020 A | 18.000 | 0 | 0 | $0 |
| Paul L Berns | Yönetim kurulu üyesi | 20 Nisan 2016 P | 117.371 | 0 | 0 | $0 |
| AWM Investment Company, Inc. | 10% sahip | 31 Aralık 2015 S | 0 | 0 | 0 | $0 |
| MARXE AUSTIN W & GREENHOUSE DAVID M | 10% sahip | 08 Eylül 2014 P | 1.142.368 | 0 | 0 | $0 |
| Stefan Loren | · | 08 Temmuz 2026 A | · | 0 | 0 | $0 |
| Dov Elefant | · | 25 Ocak 2022 A | 11.755 | 0 | 0 | $0 |
| Richard Hertzberg | · | 09 Ağustos 2016 S | 280.000 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 2 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
CLRB Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 10 analist
AL
Medyan hedef
$10.50
+489,9%
3 30,0%
Güçlü Al
6 60,0%
Al
1 10,0%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
4 analist · 2026-10-02Ortalama hedef $11.50 +546,1%
← Tüm hedeflerin altında
Mevcut fiyat $1.78
Düşük$10.00
Ortalama$11.50
Yüksek$15.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| CLRB | · | -0.4 | · | · | · | · |
| ACTU | $142M | -5.8 | · | · | -843.5% | · |
| NEUP | $24M | -1.4 | -92.5% | -1145.7% | -49.5% | · |
| DYAI | · | -4.1 | -11.6% | · | · | · |
| SHPH | $4M | -0.3 | 0.00% | · | -400.1% | · |
| MRKR | $25M | -1.9 | -46.2% | -343.0% | -89.1% | · |
| ALLR | $17M | -0.0 | · | -3509.7% | -102.1% | · |
| KPTI | $135M | -0.4 | 0.57% | -134.2% | 73.7% | · |
| KTTA | · | · | · | · | · | · |
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 13, 2026